/	PEJCA	,	
0	Please type a plus to	gn (+) inside this box	•
	IIII C	Badustian Ast of 1995	ت

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ons are required to respond to a collection of information unless it contains a valid OMB control number. NT & Socitute for form 1449A/PTO Complete if Known **Application Number** 09/751,877 INFORMATION DISCLOSURE December 28, 2000 Filing Date STATEMENT BY APPLICANT **First Named Inventor** Frances YEN, et al. Group Art Unit Unknown (use as many sheets as necessary) **Examiner Name** Unassigned **Attorney Docket Number** Sheet of 89.US3.REG

		-			U.S. PATENT DOCU	MENTS		廿
Examiner Initials	Cite No.1	U.S. Paten Number		Code ²	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1600/2900
								-8
								-8
		-						
						-		
			-					-
	<u> </u>							
								\dashv
		~				hone-Poulenc Rorer S./	August 5, 1993	

				FOR	EIGN PATENT DOCUMEN	гѕ		
Examiner Initials	Cite No.1	Office ³	Foreign Patent Doct	ument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
an	A	wo	9315198	A1	Rhone-Poulenc Rorer S.A.	August 5, 1993		
um	В	wo	0003013	A2	Amsterdam Molecular Therapeutics	January 20, 2000		
						-		
		\sqcup						_
		\vdash				ļ		├—
						<u> </u>		-
<u> </u>		┝				+		┢
								\vdash
		\vdash						

Examiner	100	Date	
Signature	(1)	Considered	11/30/02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NO E	CE	• • •	
0 "0	Please ty	plus sign (+) inside th	is box → +
MIN	Under the	perwork Reduction Act	of 1995, no person

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE as are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

Comple	te if Known	\pm
Application Number	09/751,877	
Filing Date	December 28, 2000	
First Named Inventor	Frances YEN, et al.	一
Group Art Unit	Unknown	Fi
Examiner Name	Unassigned	
Attorney Docket Number	89.US3.REG	る
N PATENT LITERATURE DO	CUMENTS	33
ETTERS), title of the article (when ap	propriate), title of the	78

			OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		E
Exan Initia		Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	ř
S	m	c	Shaikh, T.H., et al (1999) EMBL database XP002162303; ac: AC007707; Homo sapiens chromosome 11 clone 442e11 from RPCI11 Library map 11q23, complete sequence		Ĭ
		D	Lohse, P., et al., "GENETIC POLYMORPHISM OF HUMAN PLASMA APOLIPOPROTEIN A-IV IS DUE TO NUCLEOTIDE SUBSTITUTIONS IN THE APOLIPOPROTEIN A-IV GENE", J Biol Chem 1990 Jun 15;265(17):10061-4		1
		E	Lohse, P., et al., "THREE GENETIC VARIANTS OF HUMAN PLASMA APOLIPOPROTEIN A-IV", J Biol Chem 266: 13513-13518 (1991)		Ì
		F	Norman, R.A., et al., "EMPIRICALLY DETERMINED POWER CALCULATIONS FOR SINGLE LOCUS ALLELIC ASSOCIATION STUDIES", (2000) Am. J. Hurn. Gen. 67(4):320		1
		G	Osada, J. et al (1998) EMBL database XP002162305. ac: AC046409; Apolipoprotein A-IV Precursor (APO-AIV)		Ì
1		/ _H	Tenkanen, H., et al., "A NOVEL POLYMORPHISM OF APOLIPOPROTEIN A-IV IS THE RESULT OF AN ASPARAGINE TO SERINE SUBSTITUTION AT RESIDUE 127", Biochim Biophys Acta 1138: 27-33 (1992)		
					1
		-			
					j

Date Examiner 11/30/02 Considered Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 09/751,877 INFORMATION DISCLOSURE December 28, 2000 Filing Date STATEMENT BY APPLICANT Jean-Baptiste DUMAS, et al. **First Named Inventor** Art Unit 1623 (use as many sheets as necessary) Examiner Name Unassigned of Attorney Docket Number G-089 USO 3REG Sheet

			U.S. PATE	NT DOCUMENTS	
Examiner	Cita	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials		Number - Kind Code ² (if known	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-			·
		US-			
		US-			
		US-			C I
		US-			工 ,
		US-			CENTER 0 8
		US-		,	2 < (
		US-			п оп
		US-			
		US-		,	\$ ~ <
		US-			1600/ 2002 T
		US-			
		US-			3 2002 1600/2900
		US-			8
		US-			
		US-			
		US-			
	1	US-		The state of the s	
***************************************	1	US-			
	1	US-			

		FORE	IGN PATENT D	OCUMENTS		
Examiner Initials	No.1	Foreign Patent Document Country Code 3 - Number 4 - Kind Code 5 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
MA		EP 0 976 824 A	02/02/2000	Amsterdam Mol. Therap.		
	ļ	***************************************				
						ļ

				PRINCEPHEN NEW WORLD FOR CONTINUE OF THE PRINCE OF THE PRI	THE PARTY OF THE P	

Examiner Signature	C	$\gamma \sim$	Date Considered	11/30/12

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English Insurance Translation in tetrached. English language Translation is attached.



PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Complete if Known Substitute for form 1449B/PTO 09/751.877 Application Number INFORMATION DISCLOSURE December 28, 2000 First Named Inventor Jean-Baptiste DUMAS, et al. STATEMENT BY APPLICANT 1623 Group Art Unit Unassigned (use as many sheets as necessary) Examiner Name of Attorney Docket Number G-0894503 REG Sheet

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
Initials.	No.1	number(s), publisher, city and/or country where published. DATABASE EMBL Online!; Acc N° Q9UBJ3; XP002207832	
UM~		HENDRIK, N, et al. "Apolipoprotein A-V"; The Journal of Biological Chemistry, Vol 276, N°48: 44512-20, November 2001	
		元	
		NOV 0 8 2002 ECH CENTER 1600/2900	1
		ER 1600/	,
		28	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.